Patents by Inventor Thorleif Moeller
Thorleif Moeller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220133774Abstract: Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs therefor. The invention provides the use of inhibitors of microRNAs repressors of MBNL1 and/or MBNL2 genes for the manufacture of a medicinal product for the treatment of myotonic dystrophy 1. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2, thereby alleviating symptoms of the disease, especially when inhibiting repressors that are expressed in the main affected organs: skeletal muscle, heart or organs of the central nervous system. The inhibition of the microRNAs miR-23b-3p and miR-218-5p is preferred. It also provides oligoribonucleotide or oligoribonucleotide analogue antagonists suitable therefor, preferably antagomiRs directed against the microRNAs mentioned with chemical modifications that enhance their interaction with the target, their stability in vivo and their ability to penetrate into the cells and distribute throughout tissues and organs.Type: ApplicationFiled: November 12, 2021Publication date: May 5, 2022Inventors: Rubén D. ARTERO ALLEPUZ, María Beatriz LLAMUSÍ TROISI, Estefanía CERRO HERREROS, Juan M. FERNÁNDEZ COSTA, Veenu Aishwarya, Thorleif Møller
-
Patent number: 11202794Abstract: Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs therefor. The invention provides the use of inhibitors of microRNAs repressors of MBNL1 and/or MBNL2 genes for the manufacture of a medicinal product for the treatment of myotonic dystrophy 1. Inhibiting these microRNAs allows to increase the endogenous levels of the corresponding proteins MBNL1 and/or MBNL2, thereby alleviating symptoms of the disease, especially when inhibiting repressors that are expressed in the main affected organs: skeletal muscle, heart or organs of the central nervous system. The inhibition of the microRNAs miR-23b-3p and miR-218-5p is preferred. It also provides oligoribonucleotide or oligoribonucleotide analogue antagonists suitable therefor, preferably antagomiRs directed against the microRNAs mentioned with chemical modifications that enhance their interaction with the target, their stability in vivo and their ability to penetrate into the cells and distribute throughout tissues and organs.Type: GrantFiled: September 19, 2017Date of Patent: December 21, 2021Assignees: UNIVERSITAT DE VALENCIA, AUM LIFETECH, INC.Inventors: Rubén D. Artero Allepuz, María Beatriz LlamusíTroisi, Estefanía Cerro Herreros, Juan M. Fernández Costa, Veenu Aishwarya, Thorleif Møller
-
Patent number: 11104942Abstract: A method for identification of the most abundant oligonucleotide species in a library of oligonucleotides comprising more than 106 oligonucleotide species, wherein the oligonucleotides of the library of oligonucleotides are not inherently capable of exponential amplification by PCR and include a coding sequence, which is characteristic of one oligonucleotide specie of the library of oligonucleotides and only one fixed sequence, which is present in a plurality of oligonucleotide species of the library of oligonucleotides, said fixed sequence being located on a 5? side of the coding sequence, and wherein the method comprises specifically amplifying the sequence of a hybridised oligonucleotide species using the steps of: incubating the library of oligonucleotides under conditions of hybridization such as to allow complementary coding sequences to hybridize and form hybridized oligonucleotide species; extending a 3? end of one or more of the hybridised oligonucleotide species, having only one fixed sequence, to pType: GrantFiled: October 28, 2016Date of Patent: August 31, 2021Assignee: Guangdong Maijinjia Biotechnologies, Co. Ltd.Inventor: Thorleif Moeller
-
Publication number: 20190144918Abstract: The present invention discloses methods for identification of oligonucleotides by manipulation of the information content a plurality of oligonucleotides. A main object of the methods is the identification of new molecular activity such as new ligands of interest for the development of therapeutics or in the field of nanotechnology.Type: ApplicationFiled: October 28, 2016Publication date: May 16, 2019Inventor: Thorleif Moeller
-
Publication number: 20180127754Abstract: The present invention provides bivalent molecules comprising a first oligonucleotide linked to a second oligonucleotide. The first and the second oligonucleotide are preferably linked via a linking moiety. Preferably, both the first and/or the second oligonucleotide comprise an antisense sequence complementary to a cellular RNA such as mRNA or microRNA.Type: ApplicationFiled: November 10, 2017Publication date: May 10, 2018Inventors: Thorleif Moeller, Christina Udesen
-
Patent number: 9725721Abstract: The present invention provides oligomers that binds RNA that consists of a lower affinity region and a higher affinity region, wherein the monomers in the higher affinity region increases the melting temperature (i.e. affinity) of the oligomer base paired to RNA more than the monomers used in the lower affinity region, wherein said increase in melting temperature is relatively to the alternative use of DNA monomers of the same (base) sequence. The oligomers of the invention are useful for binding to target RNA such as mRNA and non-coding RNA and have the advantage that they will be less prone to off-target binding via the lower affinity region than via the higher affinity region.Type: GrantFiled: September 26, 2013Date of Patent: August 8, 2017Assignee: MIRRX THERAPEUTICSInventor: Thorleif Moeller
-
Publication number: 20170218360Abstract: The present invention describes oligonucleotides that bind to microRNA target sites in target RNAs, such as mRNAs. The oligonucleotides of the invention may mediate RNase H degradation of the target RNA, mediate RNAi of the target RNA or prevent microRNA regulation of the target RNA. The oligonucleotides of the invention are useful e.g. as research tools for studying microRNA:mRNA interactions and for therapeutic development. The present invention also describes methods of identifying microRNA target sites, methods of validating microRNA target sites, methods of identifying oligonucleotides of the invention and methods of modulating the activity of a target RNA using the oligonucleotides of the invention.Type: ApplicationFiled: April 7, 2017Publication date: August 3, 2017Applicant: Mirrx Therapeutics A/SInventor: Thorleif Møller
-
Publication number: 20160145620Abstract: The present invention provides oligomers that binds RNA that consists of a lower affinity region and a higher affinity region, wherein the monomers in the higher affinity region increases the melting temperature (i.e. affinity) of the oligomer base paired to RNA more than the monomers used in the lower affinity region, wherein said increase in melting temperature is relatively to the alternative use of DNA monomers of the same (base) sequence. The oligomers of the invention are useful for binding to target RNA such as mRNA and non-coding RNA and have the advantage that they will be less prone to off-target binding via the lower affinity region than via the higher affinity region.Type: ApplicationFiled: September 26, 2013Publication date: May 26, 2016Inventor: Thorleif MOELLER
-
Patent number: 9290767Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a micro RNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: GrantFiled: August 20, 2015Date of Patent: March 22, 2016Assignee: MIRRX THERAPEUTICS A/SInventors: Thorleif Moeller, Christina Udesen
-
Publication number: 20150344892Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a micro RNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: ApplicationFiled: August 20, 2015Publication date: December 3, 2015Inventors: Thorleif MOELLER, Christina Udesen
-
Patent number: 9145557Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a micro RNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: GrantFiled: November 23, 2011Date of Patent: September 29, 2015Assignee: MIRRX THERAPEUTICS A/SInventors: Thorleif Moeller, Christina Udesen
-
Patent number: 8951984Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a microRNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: GrantFiled: April 7, 2014Date of Patent: February 10, 2015Assignee: MirrX Therapeutics A/SInventor: Thorleif Møller
-
Publication number: 20140249206Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a microRNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: ApplicationFiled: April 7, 2014Publication date: September 4, 2014Applicant: MirX Therapeutics APSInventor: Thorleif MØLLER
-
Patent number: 8691965Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a microRNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: GrantFiled: June 13, 2008Date of Patent: April 8, 2014Assignee: Mirx Therapeutics ApsInventor: Thorleif Møller
-
Publication number: 20140031537Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a micro RNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: ApplicationFiled: November 23, 2011Publication date: January 30, 2014Applicant: MIRRX THERAPEUTICS A/SInventors: Thorleif Moeller, Christina Udesen
-
Publication number: 20130079505Abstract: The present invention provides bivalent molecules comprising a first oligonucleotide linked to a second oligonucleotide. The first and the second oligonucleotide are preferably linked via a linking moiety. Preferably, both the first and/or the second oligonucleotide comprise an antisense sequence complementary to a cellular RNA such as mRNA or microRNA.Type: ApplicationFiled: March 24, 2011Publication date: March 28, 2013Applicant: MIRRX THERAPEUTICS A/SInventors: Thorleif Moeller, Christina Udesen
-
Publication number: 20100256223Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a microRNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: ApplicationFiled: June 13, 2008Publication date: October 7, 2010Inventor: Thorleif Møller
-
Publication number: 20100021914Abstract: The present invention describes oligonucleotides that bind to microRNA target sites in target RNAs, such as mRNAs. The oligonucleotides of the invention may mediate RNase H degradation of the target RNA, mediate RNAi of the target RNA or prevent microRNA regulation of the target RNA. The oligonucleotides of the invention are useful e.g. as research tools for studying microRNA:mRNA interactions and for therapeutic development. The present invention also describes methods of identifying microRNA target sites, methods of validating microRNA target sites, methods of identifying oligonucleotides of the invention and methods of modulating the activity of a target RNA using the oligonucleotides of the invention.Type: ApplicationFiled: November 23, 2007Publication date: January 28, 2010Inventor: Thorleif Møller